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Plasma endothelin-1 levels rise in diabetes and after
exposure to contrast media suggesting a role in progressive
diabetic and acute radiocontrast nephropathies. Here we
studied individual and combined effects of streptozotocin-
induced diabetes and contrast media on renal endothelin
converting enzyme-1 levels in the rat. In vivo, medullary (but
not cortical) endothelin converting enzyme protein gradually
increased 4 to 5-fold following the induction of diabetes or
after the administration of contrast media but rose 15-fold
when diabetic rats were given contrast media. Changes in
mRNA expression paralleled those of the protein.
Immunohistochemistry confirmed that increased tubular and
endothelial cell endothelin converting enzyme-1 were most
pronounced in the medulla. In vitro, endothelin-1 levels
increased 3-fold following incubation of endothelial cells with
media high in glucose or with contrast and 4-fold with their
combination. Endothelin converting enzyme-1 protein and
mRNA expression changed in a similar pattern while prepro
endothelin-1 mRNA increased with each insult but not in an
additive way. Our study shows that diabetes and contrast
media up-regulate renal medullary endothelin converting
enzyme-1 expression and synthesis.
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Early experimental diabetes is associated with reduced renal
parenchymal oxygenation that is most prominent in the renal
medulla,1–3 a region already functioning at low oxygen tension
under normal physiologic conditions.4 The decline in renal
parenchymal pO2 predominantly reflects enhanced tubular
transport, the consequence of increased glomerular filtration
rate and solute delivery to the distal nephron, as well as to
augmented tubular mass and sodium transporters.1,3,5 A role
for altered renal hemodynamics in diabetes-associated renal
hypoxia has not been clearly defined so far,6–8 but remains a
possibility, as important regulators of renal vascular tone are
altered, such as nitrovasodilation9 and ambient adenosine
concentration.10 Distorted anatomy of the renal microcircula-
tion, related to diabetic glomerulopathy, may also play an
important role in advanced disease.11
Reduced renal oxygenation in the diabetic kidney is asso-
ciated with cellular hypoxia-adaptive response, mediated
in part through hypoxia-inducible factors.3 Diabetes predis-
poses to radiocontrast-induced nephropathy (CIN), a
common cause of acute renal failure.12–14 At any given
degree of baseline glomerular filtration rate, diabetes doubles
the risk of developing CIN as compared with nondiabetic
patients.15 The administration of iodinated radiocontrast
media (CM) acutely reduces renal parenchymal oxygena-
tion16 in a distribution pattern similar to that of diabetes-
related chronic hypoxia.17 As with diabetes, CM-induced
medullary hypoxia, reflecting enhanced oxygen consumption
for tubular transport, combined with altered regional
hemodynamics, is associated with hypoxia-inducible factor
response and is believed to play a central role in the
pathogenesis of CIN.18
Both diabetes19,20 and the administration of CM16 are
associated with enhanced endothelin-1 (ET-1) production.
As ET-1 markedly affects renal hemodynamics and tubular
transport through specific endothelin ETA and ETB recep-
tors,21 it is conceivable that it plays an important role in
the changes in renal parenchymal microcirculation and
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oxygenation observed in the diabetic kidney, and particularly
following the administration of CM.22
The biologically active endothelins are produced by
sequential proteolysis of the precursor prepro-endothelins.
The intermediate peptide, big endothelin undergoes a final
proteolysis by ubiquitous endothelin-converting enzyme
(ECE) isoforms.23,24 The role of these enzymes in the deter-
mination of the rate of endothelin synthesis remains to a
large extent unknown. We hypothesized that the major
isoform ECE-1 may play a key role in the rising circulating
and renal endothelin levels found in diabetes and after the
exposure to CM.
To test this assumption, we explored the independent and
combined effects of diabetes and CM on ECE-1 synthesis and
content in the rat renal parenchyma. Because endothelin ETB
upregulation was found in the renal medulla in rats with
congestive heart failure25 and chronic tubulointerstitial
disease,26 presumably compensating for intensified ambient
hypoxemia, we also looked for endothelin ETB receptor
upregulation in diabetic kidneys. To isolate the independent
effects of hyperglycemic environment and radiocontrast
medium upon ECE-1 synthesis, in additional experiments
we studied the effect of hyperglycemia and CM on ET-1,
prepro-ET-1, and ECE-1 expression in cultured endothelial
cells.
RESULTS
Induction of diabetes and the impact of CM
Streptozotocin (STZ)-induced diabetic rats developed hy-
perglycemia (401±9 mg per 100 ml within 48 h, as compared
with 88±2 mg per 100 ml in control animals (CTR)). As
detailed elsewhere,3 plasma insulin declined 50–33% over
2–30 days after the induction of diabetes. As shown in
Table 1, weight reduction was noted over time, along with
increasing kidney weight and kidney/body weight ratio.
Marked polyuria developed, reflecting osmotic diuresis.
This was associated with a rise in plasma urea (from
7.0±0.2 to 16.9±5.3 mmol l1, Po0.001), whereas plasma
creatinine was maintained, reflecting effective volume deple-
tion. Creatinine clearance doubled over time (from 0.41±
0.02 ml per min per 100 g in CTR to 0.81±0.22 ml per min
per 100 g by day 30, Po0.001), and fractional sodium
excretion increased from 0.49±0.04 to 0.87±0.13%
(Po0.05).
Twenty-four hours following CM administration to diabetic
rats, enhanced creatinine clearance declined by 45% (from
0.83±0.04 to 0.45±0.08 ml per min per 100 g, Po0.001), in
association with enhanced medullary hypoxia and hypoxia
adaptation. Nevertheless, renal structural integrity remained
preserved.3 In CTR animals given CM, renal structure was also
intact and kidney function remained unaltered (creatinine
clearance was 0.37±0.05 and 0.39±0.03 ml per min per 100 g
before and after CM administration, respectively).3
Kidney ECE protein and mRNA expression in STZ diabetic rats
Cortical ECE-1 protein remained largely unchanged follow-
ing the induction of diabetes, increasing by 25% (Po0.05)
only at 30 days (Figure 1a). By contrast, outer medullary ECE
markedly increased at day 7 and thereafter, rising 5-fold by
day 14 (Figure 1b) (Po0.01). The inner medulla exhibited an
early effect, which was intermediate in extent, with ECE-1
protein increasing 50% after 2 days and reaching a maximal
2-fold increment by 7 days post-STZ (Figure 1c).
Intriguingly, unlike the changes in ECE-1 protein, ECE-1
mRNA levels in the outer medulla did not change over time
(100±8, 86±20, and 97±12% at 7, 14, and 30 days of
diabetes, respectively). Similarly, cortical ECE-1 mRNA was
not altered either. By contrast, inner medullary ECE-1 mRNA
gradually rose over time, reaching 159±30, 233±25, and
297±46% of baseline, respectively (Po0.05 for the two
longest time periods vs baseline). These observations suggest
region-specific regulation pattern of ECE-1, potentially also
reflecting different transcriptional and post-transcriptional
mechanisms.
Effect of contrast media on ECE-1 protein expression
in control nondiabetic animals
In nondiabetic CTR rats, a 4-fold increase in ECE-1 protein
expression was noted in the outer medulla 24 h after the
administration of CM, as compared with nondiabetic
animals not given CM (Figure 2b) (Po0.01). By contrast,
in the cortex and inner medulla ECE protein remained
unchanged (Figure 2a and c).
Effect of contrast media on ECE-1 protein and mRNA
expression in STZ diabetic rats
In diabetic animals (day 14), cortical ECE-1 protein
remained unchanged as compared with CTR animals, but it
Table 1 | Structural and functional changes in STZ diabetic rats along time
Group (number of animals) CTR (36) D—2 days (8) D—7 days (8) D—14 days (35) D—30 days (7)
Blood glucose at killing (mg per 100 ml) 88±2 393±35c 384±22c 328±42c 380±29c
Change in body weight (g) Gain by 1–2 g day1 34±4 44±8a 50±7a 104±8c
Final 2 kidney weight (g) 3.06±0.10 3.27±0.31 2.91±0.10 3.63±0.17b 3.66±0.35
Final kidney/body weight ratio (%) 0.84±0.02 0.99±0.04 1.04±0.04 1.22±0.05c 1.58±0.07c
Urine volume (ml h1) 0.51±0.04 ND ND 5.45±0.43c 3.44±0.67c
ND, not determined; STZ, streptozotocin.
Control rats (CTR) are compared with diabetic animals (D) 2, 7, 14, and 30 days after the induction of diabetes. This table is modified from data extended from our previous
publication, using the same animals for the evaluation of cellular hypoxia response.3
aPo0.05; bPo0.01; cPo0.001 vs CTR animals, one-way analysis of variance.
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Figure 1 | Time-dependent changes in ECE-1 protein following the induction of diabetes. ECE-1 protein levels in kidney cortex
(a), outer medulla (b), and inner medulla (c) as determined by western blot analysis. The right panels indicate the densitometric analysis
for five animals in each group. CTR—control nondiabetic animals. D—diabetic. The duration of diabetes (days) is outlined on the x axis.
Diabetes increased medullary ECE-1 protein expression over time. *Po0.01 compared with nondiabetic CTR animals.
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Figure 2 | The effect of contrast media on ECE-1 protein. ECE-1 protein levels in kidney cortex (a), outer medulla (b), and inner medulla
(c) in nondiabetic control kidneys (CTR) and CTR infused with 8 ml kg1 of 60% meglumine iothalamate (CTRþCM). The right panels
indicate the densitometric analysis for five animals in each group. CM increased ECE-1 protein expression selectively in the outer medulla.
*Po0.01 compared with nondiabetic CTR animals.
Kidney International (2008) 74, 91–100 93
M Khamaisi et al.: Renal ECE-1 expression o r i g i n a l a r t i c l e
rose by 50% 24 h following the administration of CM
(Po0.01) (Figure 3a). In the outer medulla, the 5-fold
increase in ECE-1 protein levels associated with the induction
of diabetes was further increased 3-fold 24 h after the
administration of CM (altogether 15-fold increase vs CTR)
(Figure 3b) (Po0.001). In the inner medulla, although ECE
protein levels rose 2-fold in diabetic rats compared with
CTR animals (Po0.01), CM did not elicit a further rise
(Figure 3c). Changes in renal ECE-1 mRNA grossly paralleled
alterations in the ECE-1 protein level, with outer medullary
mRNA rising 2.9-fold 24 h following CM.
ECE-1 and endothelin ETB receptor expressions
Immunohistochemistry was applied to define the renal cell
types expressing ECE-1. As shown in Figure 4, in the intact
rat kidney, ECE-1 was widely expressed in tubular cells,
principally in collecting ducts and medullary thick ascending
limbs, and most prominently within the renal medulla. It was
also expressed in glomerular podocytes and in vasa recta
within the outer medulla.
As illustrated in Figure 5, although ETB immunostaining
was faint at the outer medulla in CTR animals, in diabetic
animals vasa recta and peritubular interstitial cells became
strongly immunopositive in over 90% of samples at all time
points throughout days 2–30 (n¼ 3–5 for the different time
points).
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Figure 3 | The effect of diabetes and contrast media on renal ECE-1 protein. ECE-1 protein levels in kidney cortex (a), outer medulla (b),
and inner medulla (c) in nondiabetic (CTR), 14 days diabetic (D), and 14 days diabetic animals infused with 8 ml kg1 of 60% meglumine
iothalamate (DþCM). The right panels indicate the densitometric analysis for five animals in each group. Data are mean±s.e.m.
Medullary ECE-1 protein increased in diabetic animals and were further augmented in the outer medulla and cortex following the
administration of radiocontrast. *Po0.001 compared with nondiabetic CTR animals. **Po0.01 compared with nondiabetic CTR animals.
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Figure 4 | ECE-1 immunostaining in intact rat kidney. ECE-1
protein immunostaining in CTR kidneys, with representing sections
at the cortex (a), outer stripe (b), and inner stripe of the outer
medulla (c—longitudinal section; d—tangential section). Arrow¼
glomerular cell, most likely podocyte; asterisk¼ either unspecified
distal tubule in the cortical labyrinth or thick ascending limb in the
medulla; CD¼ collecting duct; PT¼proximal tubule; and
VB¼ vascular bundle. PTs are all negative (a and b), whereas strong
perinuclear signals appear in most CDs of all renal zones (a–d).
Additional signals appear in glomeruli (a), in distal tubules (a–d), and
in interstitial and/or endothelial cells of the medulla (c and d),
including VBs (d). Original magnification  250.
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In vitro findings
Incubation of cultured endothelial cells at high glucose
concentration significantly increased ET-1 levels already
by 6 h (data not shown) reaching a 2.8-fold increase by
24 h (Figure 6). This was associated with a 30% increase
in prepro-ET-1 mRNA at that time point (Figure 6). ECE-1
protein and mRNA levels were also raised by 70 and 20%,
respectively (Figure 7).
Incubation with CM for 24 also resulted in a 3-fold rise in
ET-1, associated with a 45% increase in prepro-ET-1 mRNA.
ECE-1 protein and mRNA rose 80 and 25%, respectively
(Figures 6 and 7).
The increase in all the above parameters was generally
more pronounced when cells were incubated for 24 h conco-
mitantly at high glucose concentration, and with the presence
of CM. ET-1 increased 4-fold, and ECE-1 protein and mRNA
rose 220 and 45%, respectively. The rise in prepro-ET-1
(30%), however, was not further augmented by the addition
of CM, and was identical to that observed with high glucose
alone (Figures 6 and 7).
Noteworthy, increased medium osmolality by the addition
of mannitol or hypertonic saline to levels comparable to the
tested conditions of high glucose±CM did not exert a rise
in ET-1 levels (data not shown), in agreement with previous
reports,16,27 suggesting a metabolic-mediated effect of
glucose/CM, rather than the increase in osmolality per se.
In complementary studies, the direct impact of hypoxia
upon ECE-1 was tested. Incubation of human vascular
endothelial cells under hypoxic conditions resulted in a
modest increase in cell death: the fractional released lactate
dehydrogenase (LDH) activity over 24 h, expressed as the
percentage of the total LDH activity, was 10±4 and 22±6%
following normoxic and hypoxic incubations, respectively.
Nevertheless, released ET-1 levels rose significantly, and ECE-
1 protein expression increased (by 64 and 40%, respectively,
Po0.05). In additional preliminary experiments, attenuation
of oxidative stress by the addition of N-acetylcysteine
(1 mmol l1), substantially blunted the increase in ET-1
levels and ECE-1 expression, invoked by high glucose
concentration, by 62 and 48%, respectively (Po0.05).
DISCUSSION
The formation of ET-1, the most prevalent biologically active
member of the endothelin family, is initiated by furin-
like enzymes, which cleave the pro-hormone (prepro-
endothelin), and generate big endothelin. Subsequently,
big endothelin undergoes a second proteolytic step by ECE
isoforms and is cleaved into mature, active endothelins at
the Trp21-Val/Ile22 bonds.24,28–31
Although most studies of endothelin induction focus
on the generation of prepro endothelin data regarding
the regulation of the final and perhaps critical step, namely
ECE synthesis and activity are limited. Herein, we report
increased ECE-1 expression in the renal parenchyma in
diabetes and following CM administration. This increase
most likely contributes to the elevated circulating and renal
ET-1, reported in these two conditions.32,33
Of the two currently known ECE isoforms, ECE-1 has a
broader tissue distribution, always expressed at higher levels
than ECE-2 and has a central role in the endothelin system.34
ECE-1 belongs to the neprilysin family of zinc metallo-
peptidases,28,29 and is abundantly expressed in the vascular
VR VR
Figure 5 | ETB immunostaining: the effect of diabetes. ETB
immunostaining of CTR (a) and 14-day STZ diabetic kidneys
(b). These are horizontal cross-sections at the outermost level
of the inner stripe of the outer medulla, illustrating vasa recta
(vascular bundle, VB), surrounded by tubular components
(medullary thick and thin limbs, and collecting ducts). Intense
ETB immunostaining is noted in the diabetic kidney in vasa recta
and peritubular vascular endothelial/interstitial cells. Original
magnification  400.
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Figure 6 | ET-1 and prepro-ET-1 expressions in culture
endothelial cells. ET-1 released into the culture medium (a)
and prepro-ET-1 mRNA in cultured endothelial cells (b). Cells
were incubated for 24 h with either 5.5 or 22.5 mmol l1 glucose,
with or without concomitant exposure to meglumine iothalamate
(9.7 mg per 100 ml iodine). Both ET-1 and prepro-ET-1 mRNA
rose under hyperglycemic conditions and further increased with
co-exposure to radiocontrast. Values represent the mean±s.d.
of three experiments in triplicate. *Po0.04 compared with
5.5 mmol l1 glucose. **Po0.03 compared with 5.5 mmol l1
glucose, 22.5 mmol l1 glucose, and to 5.5 mmol l1
glucoseþ iothalamate.
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endothelial cells of all tissues but is also found in nonvascular
cells.35–39 As a type II membrane protease, it is characterized
by a single transmembrane region, a short NH2-terminal
cytosolic tail, and a large COOH-terminal extracellular
domain that contains the enzymatic active site.30
The potential role of ECE-1 in the regulation of endothelin
synthesis has been explored in a few settings. In vitro, we have
shown previously that ECE-1 protein and mRNA levels were
elevated in endothelial cells incubated in high glucose media.27
By contrast, ECE-1 mRNA expression in the renal cortex,
medulla, and papilla was similar in Prague hypertensive rat and
in normotensive counterpart.40 High salt intake was reported to
increase medullary ECE-1,41 whereas experimental congestive
heart failure stimulated cortical ECE-1 expression.42 In rats
acutely injected with cyclosporine A, an inverse association was
found between ET-1 and ECE-1. Whereas prepro-ET-1 rapidly
rose within 30–60 min, followed by an increase in plasma ET-1,
ECE-1 mRNA was downregulated over 1–24 h in the glomeruli
and along all nephron segments (both in vivo and in vitro), and
ECE-1 protein levels declined in the outer and inner medulla
for as long as 96 h after exposure. ECE-1 mRNA recovered only
72 h after the administration of cyclosporine A.43 The authors
concluded that enhanced ET-1 levels following cyclosporine A
exposure principally reflect upregulated prepro-ET-1 mRNA
and synthesis, whereas glomerular and tubular ECE-1 (as well
as ET receptor subtypes) is downregulated, perhaps as an
adaptive response to enhanced ET synthesis.
Diabetes and radiocontrast agents are also associated
with increased ET-1 levels, and ET-1 is believed to participate
both in the pathogenesis of diabetic nephropathy44 and in
radiocontrast-induced acute renal dysfunction.45 Interest-
ingly, Clark et al.46 found that ET-1 levels, already high at
baseline, rose most pronouncedly in diabetic patients follow-
ing radiocontrast studies. In the perspective of this obser-
vation, together with the peculiar susceptibility of diabetics
to radiocontrast nephropathy it is tempting to assume that
ET-1 has an important role in this disorder. Indeed, the
administration of bosentan, a nonselective endothelin ETA/
ETB receptor antagonist reduced albuminuria, increased
glomerular filtration rate, and ameliorated mesangial matrix,
fibronectin, and type IV collagen accumulation in diabetic
rats.47 Similarly, the selective inhibition of ETA receptors
attenuates radiocontrast-induced medullary hypoxia48 and
has been suggested as a preventive measure against the
development of contrast nephropathy in high-risk patients.49
Increased prepro-ET-1 mRNA was reported both in
diabetes50 and in cultured endothelial cells following the
exposure to radiocontrast.51 We also reported rising plasma
ET-1 shortly after the administration of CM in vivo.16 Our
prepro-ET-1 findings in vitro are in accordance with these
studies. The novel findings reported in the present series,
both in vivo and in vitro, imply that increased ET-1 produc-
tion in diabetes and following CM exposure may be mediated
to a large extent by ECE-1 upregulation. Furthermore, the
particularly pronounced upregulation of ECE-1 in diabetic
animals following the administration of contrast medium,
paralleling clinical evidence for highest ET-1 levels,46 suggests
a causal role for ECE-1/endothelin in contrast nephropathy,
principally in the diabetic population. Further experiments,
using knockout animals and selective ET-receptor antagonists
are required to address this possibility.
The mechanisms controlling ECE-1 expression at various
renal regions are yet to be defined. Our experiments in vitro
indicate that the well-known upregulation of ET-1 under
hypoxia52 is associated with a parallel increase in ECE-1. Both
experimental3 and advanced human diabetes53 are associated
with renal parenchymal hypoxia, as also happen following
radiocontrast administration,18 particularly in the diabetic
kidney.3 Therefore, it is tempting to assume that hypoxia
plays a role in the induction of ECE-1. Nevertheless, hypoxia
may not be the sole mechanism, as we found ECE-1 induc-
tion by high glucose concentration or CM in vitro under
normoxic conditions. Reactive oxygen species, generated in
the diabetic kidney and following CM administration are
additional potential mediators of ECE-1 upregulation. Our
preliminary findings in vitro, showing attenuation of
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Figure 7 | ECE-1 protein and mRNA in cultured endothelial
cells. ECE-1 protein densitometry (a), immunoblot (b), and mRNA
(c) in cultured endothelial cells. Cells were incubated for 24 h with
either 5.5 or 22.5 mmol l1 glucose, with or without concomitant
exposure to meglumine iothalamate (9.7 mg per 100 ml iodine).
Both ECE-1 protein and mRNA rose under hyperglycemic
conditions and further increased with co-exposure to
radiocontrast. Values represent the mean±s.d. of 2 3
experiments in total. *Po0.01 compared with 5.5 mmol l1
glucose. **Po0.05 compared with 5.5 mmol l1 glucose,
22.5 mmol l1 glucose, and to 5.5 mmol l1 glucoseþ iothalamate.
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ECE-1 upregulation with N-acetylcysteine support this
possibility. However, so far reactive oxygen species were
found to downregulate ECE-1 expression54 and activity.55
The intracellular mechanisms that lead to ECE induction are
currently studied, and, apparently, ECE upregulation during
hyperglycemia is mediated by protein-kinase C-d (Khamaisi
and Raz unpublished data).
Noteworthy, in our hands, ECE-1 protein levels and mRNA
expression in vivo did not fully correspond, and were regulated
in a region-specific manner. As mRNA measurements largely
depend on quick tissue recovery and preservation, and in the
presence of fully paralleled findings in cell cultures, this dys-
synchrony in vivo conceivably reflects flawed tissue collection,
particularly during the difficult time-consuming separation of
the outer medulla. Alternatively, the dys-synchrony in vivo
may reflect differences in the half-life of mRNA and the
protein, or post-transcription mechanisms.
We also report the upregulation of ETB in vasa recta and
peritubular capillaries in the outer medulla in STZ diabetic
kidneys. Comparable pattern of ETB upregulation and distribu-
tion in the outer medullary microcirculation has previously
been observed in animals with compensated heart failure25 and
following the induction of chronic tubulointerstitial disease,
associated with medullary hypoxia.26 The parallel expression of
ECE-1 protein and ETB receptors in medullary vasa recta
(Figures 4d and 5) conceivably reflects a local apocrinic pattern
of hormone function. Interestingly, although ET-1 is a most
potent vasoconstrictor in most vascular beds, it induces selective
outer medullary vasodilation, mediated by ETB receptors and
nitric oxide.25,56 We speculate that outer medullary ETB
upregulation serves to maintain regional blood flow and
oxygenation, as an adaptive response to increased endothelin
concentrations and ambient hypoxia, noted in the diabetic
kidney.3 Indeed, severe hypertension and renal dysfunction
develops in ETB-deficient diabetic rats.
57 In that respect,
aggravation of contrast nephropathy in humans with the use
of the nonselective ETA/ETB receptor antagonist bosentan
58
probably underscores the important role of ETB receptors in
maintaining medullary oxygen sufficiency and integrity.59
In conclusion, evidence gathered so far suggests that ET-1
may be involved in the pathogenesis of chronic diabetes
complications and in contrast nephropathy. Our findings
imply that ECE-1 may play a key role in the upregulation of
ET-1 levels under both circumstances, and propose an
explanation for the particular susceptibility of diabetic
patients to contrast media. In that perspective, ECE-1 may
serve as a potential target for the development of new classes
of drugs, designed for the prevention of diabetic complica-
tions and contrast nephropathy. Our findings and hypotheses
should be further validated by clinical studies using ECE-1
inhibitors and ET receptor antagonists.
MATERIALS AND METHODS
Animals and materials
Male Sprague–Dawley rats 250–350 g were used, fed on regular chaw
and given free excess to water. Experiments were conducted in
accord with the NIH Guide for the Care and Use of Laboratory
Animals. Chemicals were purchased from Sigma (St Louis, MO,
USA), if not stated otherwise. Rat anti-ECE-1 primary monoclonal
antibody used for western blot analysis and immunohistochemistry
was kindly received from Dr Rina Meidan (Rehovot, Israel). Anti-
ETB primary monoclonal antibodies were obtained from Alomone
Labs (Jerusalem, Israel), and the real-time PCR reagents were
purchased from Agentek (Tel Aviv, Israel). LDH-L diagnostic
reagent was purchased from Pointe Scientific Inc. (Canton, MI,
USA).
In vivo experiments
Diabetes was induced by intraperitoneal injection of freshly
prepared STZ (65 mg per kg body weight, dissolved in 100 mmol l1
citric acid, pH 4.5), and confirmed 48 h later by blood glucose
sampling from the tail tip.60 Over 80% of injected animals were
enrolled, with fed glucose levels 4250 mg per 100 ml. The animals
were kept two in a cage and studied 2, 7, 14, and 30 days later.
Persistence of hyperglycemia was confirmed again before the animals
were killed. Vehicle-injected animals served as controls.
In separate experiments, CTR and diabetic animals (14 days old)
were infused with CM (8 ml kg1 of 60% meglumine iothalamate;
Mallinckrodt, St Louis, MO, USA), and were killed 24 h later.
Vehicle-injected animals served as controls. The 14-day time point
was chosen as it yielded the most intense medullary hypoxia3 and
ECE-1 expression.
The animals fed on regular rat chaw and water ad libitum, were
kept in metabolic cages (Nalge, Rochester, MD, USA) for urinary
collection. Corresponding blood samples were obtained after the
animals were killed. Kidney functional parameters were obtained
and detailed in a previous publication, exploring renal hypoxia
adaptation.3 At the time indicated, animals were killed under
anesthesia (pentobarbital, 60 mg kg1). In some of the experiments,
one or the two kidneys were perfusion fixed for morphology and
immunohistochemistry. Non-perfusion-fixed kidneys were hastily
removed, and rinsed in iced saline. Samples from the cortex, outer,
and inner medulla (papilla) were collected, snap-frozen in liquid
nitrogen, and kept in 70 1C until analyzed.
In vitro studies
As vascular endothelial cells are the major source of endothelin
synthesis, we used these cells to evaluate the isolated and inde-
pendent effects of high glucose media and radiocontrast on the
endothelin system. EA.hy926 cells, human umbilical vein endothelial
cells fused with a human pulmonary epithelial cell line (A549), were
cultured in Dulbecco’s modified Eagle’s medium as described by
Waxman et al.61 Cells were positively stained for von Willebrand
factor using human anti-rabbit factor VIII antibody (Dako,
Glostrup, Denmark).
For the experiments, cells were grown in 6-well plates condi-
tioned with 5.5 mmol l1 glucose (CTR cell) and were compared
with cells incubated at high glucose concentration (22.5 mmol l1),
with meglumine iothalamate (9.7 mg iodine per ml) or under the
combined effect of high glucose and CM, for 1–24 h. Culture cell
medium osmolarity was adjusted by adding mannitol or hypertonic
saline to CTR cell culture. ET-1 levels were determined in the culture
medium, while cells were used for the determination of prepro-ET-1
and ECE-1 protein and mRNA at the 24 h time point. ET-1 levels
were determined using EIA kit (Cayman Chemical, Ann Arbor, MI,
USA) in supernatants from different cell cultures as described
before.62
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For the hypoxic insult experiments, EA.hy926 cells, cultured
in regular medium, were kept at 1% oxygen levels for 24 h, as
described previously.63 Oxygen tension was determined by an
electronic oxygen sensor coupled to an oxygen monitor (Hudson
RCI, Hanover, Germany). Cell death was measured at the end of the
hypoxic insult by the release of LDH into the medium, as previously
described.63 ET-1 levels in supernatants were determined using EIA
kit as described before.62 Total cell lysate was used for determination
of ECE-1 protein expression as described below.
Western blot analysis for determination of ECE-1 protein
expression
In vitro. At different time points, cells were washed with
phosphate-buffered saline, lysed with lysis buffer (10 mmol l1 Tris,
pH 7.4; 150 mmol l1 NaCl; and 1% NP-40) and centrifuged for
10 min at 10 000 r.p.m. at 4 1C. Supernatants were solubilized with
SDS-polyacrylamide gel electrophoresis sample buffer.
In vivo. Total tissue lysate fractions were prepared from the
cortex, the outer medulla, and the inner medulla of rat kidney as
described previously.41 Rats were killed at 2, 7, 14, and 30 days after
the induction of diabetes. Kidneys were rapidly removed and
transferred into phosphate-buffered saline on ice. Kidneys were
sliced and separated into blocks of cortex, outer medulla, and inner
medulla with a razor blade. Each part was minced and homogenized
with five strokes at 1000 r.p.m., using a glass homogenizer, in lysis
buffer (40 mmol l1 Tris-HCl, 20% glycerol, 500 mmol l1 NaCl,
6 mmol l1 ethylenediaminetetraacetic acid, 6 mmol l1 ethylenegly-
col tetraacetate, 1% NP40, 2 mmol l1 p-nitrophenylphosphate,
40 mmol l1 b-glycerol phosphate, 1 mmol l1 NaVO4, 2 mol l
dithiothreitol, 1 mmol l1 phenylmethylsulfonyl fluoride, 10 mg ml1
aprotinin, 10 mg ml1 leupeptin, pH 7.4) at 4 1C. The supernatant
was collected after centrifugation at 10 000 r.p.m. for 15 min at 4 1C
and stored at 70 1C until used. Protein concentrations were
quantified using Bio-Rad protein assay reagent with bovine serum
albumin as standard.
Total cell lysates (10 mg) or 75 mg of tissue protein lysate
were electrophoretically fractionated on 7.5% SDS-polyacrylamide
gel electrophoresis minigels and were electroblotted onto a nitro-
cellulose membrane. The membrane was sequentially incubated in
TBS that contained 3% casein for 120 min and diluted (1:1000)
bovine ECE-1 polyclonal antibody64 in TBS for 12 h on a shaker at
4 1C. The blot was washed with TBS that contained 0.1% Tween-20
and was incubated with a 1:1000 dilution of horseradish peroxidase-
conjugated goat anti-rabbit secondary antibody (Jackson Immu-
noResearch Lab, West Grove, PA, USA) in TBS for 1 h at room
temperature, washed with TBS, and incubated with the peroxidase
substrate. Immunoreactive bands were visualized within 10 min
using an ECL detection kit (Amersham Pharmacia Biotech,
Piscataway, NJ, USA).65
Real-time PCR for determination of ECE-1 and prepro-ET-1
mRNA expression
We used previously established semiquantitative real-time PCR
assays66 for ECE-1 expression. To monitor complementary DNA
synthesis efficiency, glyceraldehyde-3-phosphate dehydrogenase was
used as an internal CTR. As reported previously,41,34 total RNA from
the cells and kidney parts were extracted using the TRI Reagent
according to the manufacturer’s instructions. Complementary DNA
was synthesized by reverse transcription of cellular RNA as
previously described using the high capacity complementary DNA
reverse transcription kits (Applied Biosystems, Foster City, CA,
USA). PCR primers for amplifying rat ECE-1 were selected from the
rat gene sequence as previously reported.67 The glyceraldehyde-3-
phosphate dehydrogenase, ECE-1, and prepro-ET-1 complementary
DNA were PCR amplified using primers obtained from Agentek.
ECE-1 sequence was PCR amplified using a similar procedure except
that the number of cycles was increased to 30 and the annealing
temperature was increased to 58 1C. A dissociation curve analysis was
run after each real-time experiment to confirm the presence of only one
product and the absence of formation of primer dimmers. The
threshold cycle number (Ct) for each tested gene X was used to quantify
the relative abundance of the gene: 2(Ct gene X–Ct G3PDH) 1000.
Endothelin ETB receptor immunohistochemistry
As we have previously reported upregulation of renal medullary
endothelin ETB receptors under conditions threatening medullary
oxygen sufficiency,25,26 we complemented these series by looking at
the effect of diabetes upon renal endothelin ETB expression. CTR
and diabetic kidneys (2–30 days) were perfusion fixed with
paraformaldehyde through the abdominal aorta, stored in ice-
cooled phosphate-buffered saline, and processed for paraffin
embedding as previously detailed.3 Three-micron paraffin sections
were processed for routine histology and immunohistochemistry.
Hematoxylin and eosin staining was performed according to
standard procedures. Immunohistochemistry was carried out using
the anti-ETB primary monoclonal antibodies (1:200).
ECE-1 immunohistochemistry
As paraffin sections proved inappropriate for this staining—
despite of antigen retrieval techniques like cooking or proteinase
digestion—we employed 5 mm cryostat sections. To avoid freez-
ing artifacts, perfusion-fixed kidneys were kept for 2 h in
800 mosmol l1 sucrose in phosphate-buffered saline (pH 7.4,
4 1C), after which they were snap-frozen in isopentane cooled
by liquid nitrogen. Immunohistochemistry was carried out with
the help of a catalyzed signal amplification (CSA) kit from
Dako (Hamburg, Germany) using rabbit-anti ECE-1 antibody
(1:10 000).
Statistics
Data are represented as means±s.d. Student’s t-test and multiple
comparisons with T-test post hoc analysis of variance were used
as indicated below for the comparison of protein and mRNA
parameters. Statistical significance was set at Po0.05.
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